Despite a $465 million settlement with the U.S. Justice Dept., Mylan (NSDQ:MYL) is still under fire for misclassifying its EpiPen auto-injector with the Centers for Medicare & Medicaid Services. Last week, the Securities & Exchange Commission’s enforcement division launched an investigation into the Canonsburg, Pa.-based company’s history with CMS; yesterday investors filed a purported class action seeking compensation for damages.
The lawsuit was filed in a New York district court, claiming that Mylan knowingly misled investors and issued false and misleading statements about the emergency allergy treatment. The group is seeking “compensation for all those who purchased or otherwise acquired Mylan N.V. ordinary shares and/or Mylan Inc. common stock” between February 2013 and October 2016.
Get the full story at our sister site, Drug Delivery Business News.